Is methylphenidate a safe and effective treatment for ADHD-like symptoms in children with pervasive developmental disorders?

Noah L. Miller, Robert L Findling

Research output: Contribution to journalArticle

Abstract

Children with autistic disorder and related pervasive developmental disorders (PDDs) frequently have symptoms of hyperactivity and impulsivity similar to the symptoms of attention-deficit/hyperactivity disorder (ADHD). Clinicians often treat these symptoms with methylphenidate (MPH), but historically there are little available data about the use of MPH in children with PDD. The Research Units on Pediatric Psychopharmacology (RUPP) group set out to determine whether MPH is a safe and effective treatment for the ADHD-like symptoms associated with PDD. MPH was found to be superior to placebo in reducing hyperactivity scores on the Aberrant Behavior Checklist. However, there was a lower magnitude of response and a higher incidence of medication discontinuation than previously reported in typically developing children with ADHD. Although MPH seems to be a reasonable choice for the treatment of ADHD-like symptoms in children with PDD, clinicians should consider the findings from the RUPP MPH study before prescribing MPH to children with PDD.

Original languageEnglish (US)
Pages (from-to)1025-1028
Number of pages4
JournalExpert Opinion on Pharmacotherapy
Volume8
Issue number7
DOIs
StatePublished - May 2007
Externally publishedYes

Fingerprint

Methylphenidate
Attention Deficit Disorder with Hyperactivity
Psychopharmacology
Therapeutics
Pediatrics
Impulsive Behavior
Autistic Disorder
Checklist
Research
Placebos
Incidence

Keywords

  • ADHD
  • Asperger's disorder
  • Attention-deficit/hyperactivity disorder
  • Autism
  • Autistic disorder
  • Methylphenidate
  • Pervasive developmental disorder

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

@article{8e88b4c6ecd14c228dbecaf2dd1209e0,
title = "Is methylphenidate a safe and effective treatment for ADHD-like symptoms in children with pervasive developmental disorders?",
abstract = "Children with autistic disorder and related pervasive developmental disorders (PDDs) frequently have symptoms of hyperactivity and impulsivity similar to the symptoms of attention-deficit/hyperactivity disorder (ADHD). Clinicians often treat these symptoms with methylphenidate (MPH), but historically there are little available data about the use of MPH in children with PDD. The Research Units on Pediatric Psychopharmacology (RUPP) group set out to determine whether MPH is a safe and effective treatment for the ADHD-like symptoms associated with PDD. MPH was found to be superior to placebo in reducing hyperactivity scores on the Aberrant Behavior Checklist. However, there was a lower magnitude of response and a higher incidence of medication discontinuation than previously reported in typically developing children with ADHD. Although MPH seems to be a reasonable choice for the treatment of ADHD-like symptoms in children with PDD, clinicians should consider the findings from the RUPP MPH study before prescribing MPH to children with PDD.",
keywords = "ADHD, Asperger's disorder, Attention-deficit/hyperactivity disorder, Autism, Autistic disorder, Methylphenidate, Pervasive developmental disorder",
author = "Miller, {Noah L.} and Findling, {Robert L}",
year = "2007",
month = "5",
doi = "10.1517/14656566.8.7.1025",
language = "English (US)",
volume = "8",
pages = "1025--1028",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Is methylphenidate a safe and effective treatment for ADHD-like symptoms in children with pervasive developmental disorders?

AU - Miller, Noah L.

AU - Findling, Robert L

PY - 2007/5

Y1 - 2007/5

N2 - Children with autistic disorder and related pervasive developmental disorders (PDDs) frequently have symptoms of hyperactivity and impulsivity similar to the symptoms of attention-deficit/hyperactivity disorder (ADHD). Clinicians often treat these symptoms with methylphenidate (MPH), but historically there are little available data about the use of MPH in children with PDD. The Research Units on Pediatric Psychopharmacology (RUPP) group set out to determine whether MPH is a safe and effective treatment for the ADHD-like symptoms associated with PDD. MPH was found to be superior to placebo in reducing hyperactivity scores on the Aberrant Behavior Checklist. However, there was a lower magnitude of response and a higher incidence of medication discontinuation than previously reported in typically developing children with ADHD. Although MPH seems to be a reasonable choice for the treatment of ADHD-like symptoms in children with PDD, clinicians should consider the findings from the RUPP MPH study before prescribing MPH to children with PDD.

AB - Children with autistic disorder and related pervasive developmental disorders (PDDs) frequently have symptoms of hyperactivity and impulsivity similar to the symptoms of attention-deficit/hyperactivity disorder (ADHD). Clinicians often treat these symptoms with methylphenidate (MPH), but historically there are little available data about the use of MPH in children with PDD. The Research Units on Pediatric Psychopharmacology (RUPP) group set out to determine whether MPH is a safe and effective treatment for the ADHD-like symptoms associated with PDD. MPH was found to be superior to placebo in reducing hyperactivity scores on the Aberrant Behavior Checklist. However, there was a lower magnitude of response and a higher incidence of medication discontinuation than previously reported in typically developing children with ADHD. Although MPH seems to be a reasonable choice for the treatment of ADHD-like symptoms in children with PDD, clinicians should consider the findings from the RUPP MPH study before prescribing MPH to children with PDD.

KW - ADHD

KW - Asperger's disorder

KW - Attention-deficit/hyperactivity disorder

KW - Autism

KW - Autistic disorder

KW - Methylphenidate

KW - Pervasive developmental disorder

UR - http://www.scopus.com/inward/record.url?scp=39049117623&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39049117623&partnerID=8YFLogxK

U2 - 10.1517/14656566.8.7.1025

DO - 10.1517/14656566.8.7.1025

M3 - Article

C2 - 17472547

AN - SCOPUS:39049117623

VL - 8

SP - 1025

EP - 1028

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 7

ER -